Background: Autologous breast reconstruction using abdominally based flaps is common post‐mastectomy, but donor‐site pain often leads to prolonged opioid use. The transversus abdominis plane ( TAP ) block is a common regional anesthesia technique, with bupivacaine as the standard anesthetic. Liposomal bupivacaine ( LB ), a prolonged‐release formulation, aims to extend pain relief and reduce opioid consumption, though its efficacy remains debated. Objective: This systematic review and meta‐analysis compared LB versus plain bupivacaine ( PB ) in TAP blocks for autologous breast reconstruction, focusing on opioid consumption, pain scores, and hospital stay. Methods: A systematic search identified randomized controlled trials and observational studies comparing LB (with or without PB ) to PB in TAP blocks. Data were pooled using a random‐effects model ( I2 ≥ 25%) or fixed‐effects model ( I2 < 25%). Results: Six studies (429 patients) met inclusion criteria. LB was associated with significant reduction in opioid consumption on postoperative days ( POD ) 1 ( MD = −4.99 mg; 95% CI : [−8.42; −1.56], p < 0.01, I2 = 0%) and POD 2 ( MD = −3.35 mg; 95% CI : [−5.74; −0.96], p < 0.01, I2 = 0%). Pain scores were significantly lower on POD 2 and POD 3. No difference in hospital stay was found ( MD = −0.17; 95% CI : [−0.52; 0.18], p = 0.34, I2 = 83.1%). Conclusion: LB reduced opioid consumption during the first 48 h postoperatively and modestly improved pain control on POD 2 and POD 3, but did not shorten hospital stay. Further large‐scale RCTs are needed to validate its benefits.
Oncologic patients often misunderstand the benefits and toxicities of palliative-intent therapies. This exploratory, single-center study investigated how these perceptions evolve, their impact on end-of-life (EOL) care quality, and regret. English-speaking adults were surveyed longitudinally about treatment expectations. Patient perceptions were compared to their oncologists’ assessments. Of 119 patients (mean age 65, 61.8% male), 80 (67%) completed at least 1 follow-up survey. Patients’ perceptions of treatment response, symptom palliation, and survival did not become more accurate over time. Perceptions over cure tended to become more accurate, and perceptions of toxicity were consistently accurate. Among deceased participants ( n = 47), 55.1% experienced poor quality EOL care, based on a composite measure of EOL quality. Perception accuracy at baseline was not associated with EOL quality outcomes ( P = .93). Patients with hospice involvement had less accurate perceptions ( P = .03). Twenty-nine patients completed the end-of-treatment survey, none expressed regret. Findings suggest patients’ expectations of treatment do not become more accurate over time. EOL outcomes were not associated with more accurate perceptions. Surviving patients did not regret treatment.